NOD2/CARD15 does not influence response to infliximab in Crohn's disease

S. Vermeire, E. Louis, P. Rutgeerts, M. de Vos, A. van Gossum, J. Belaiche, P. Pescatore, R. Fiasse, P. Pelckmans, R.F.M. Vlietinck, F. Merlin, al. et

Research output: Contribution to journalArticleAcademicpeer-review

188 Citations (Scopus)

Abstract

NOD2/CARD15 does not influence response to infliximab in Crohn's disease.

Vermeire S, Louis E, Rutgeerts P, De Vos M, Van Gossum A, Belaiche J, Pescatore P, Fiasse R, Pelckmans P, Vlietinck R, Merlin F, Zouali H, Thomas G, Colombel JF, Hugot JP; Belgian Group of Infliximab Expanded Access Program and Fondation Jean Dausset CEPH, Paris, France.

Department of Gastroenterology, UZ Gasthuisberg, Leuven, Belgium.

BACKGROUND & AIMS: NOD2/CARD15 was recently identified as the first gene underlying Crohn's disease (CD) susceptibility. Monoclonal antibodies to tumor necrosis factor (TNF)-alpha (infliximab) are a potent treatment for CD, with about 70% of patients responding. It is not clear which factors influence treatment outcome. We assessed whether variants in NOD2/CARD15 are predictive for differences in clinical response. METHODS: Two hundred forty-five CD patients (86 fistulizing, 159 luminal) receiving infliximab in an expanded access program were genotyped for the 3 main associated variants of NOD2/CARD15, without knowledge of the treatment response. Short-term clinical response was assessed at 4 weeks (refractory) or 10 weeks (fistulizing) after first infliximab infusion, and the mean duration of response was calculated. In a subgroup of patients, production of TNF in response to lipopolysaccharide (LPS) in mucosal biopsy tissue was also determined by means of immunoassay, and results were related to the different NOD2/CARD15 genotypes. RESULTS: In total, 32.6% of patients carried mutations in NOD2/CARD15 (18.8% R702W, 8.6% G908R, and 10.2% 1007fs) compared with 15% in controls (P < 0.001). Despite observed differences in TNF production in mucosal biopsy tissue, there was no relationship between the overall presence of a mutation in NOD2/CARD15 or of any of the mutations separately and short-term infliximab response or response duration. Furthermore, multivariate analysis could not identify clinical characteristics that, in combination with NOD2/CARD15 mutations, were associated with response to infliximab. CONCLUSIONS: In this cohort of CD patients, the frequency of NOD2/CARD15 mutations was significantly greater than that of healthy controls. However, NOD2/CARD15 was not predictive of treatment outcome with infliximab in CD
Original languageEnglish
Pages (from-to)106-111
Number of pages6
JournalGastroenterology
Volume123
Issue number1
DOIs
Publication statusPublished - 1 Jan 2002

Cite this

Vermeire, S., Louis, E., Rutgeerts, P., de Vos, M., van Gossum, A., Belaiche, J., Pescatore, P., Fiasse, R., Pelckmans, P., Vlietinck, R. F. M., Merlin, F., & et, A. (2002). NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology, 123(1), 106-111. https://doi.org/10.1053/gast.2002.34172